Sterilization for CHIPS Act Fabs: What 18 New Semiconductor Facilities Mean for Contamination Control

In August 2022, the U.S. government passed the CHIPS and Science Act, authorizing $52.7 billion in federal funding for domestic semiconductor manufacturing and research. The legislation was a direct policy response to the supply chain vulnerabilities exposed during the 2020–2022 chip shortage — a period during which the absence of domestic semiconductor capacity disrupted automotive production, consumer electronics, and defense procurement simultaneously.

The downstream consequence of that legislation is now visible in construction permits, groundbreaking announcements, and capital expenditure disclosures across the semiconductor industry. Eighteen new fabrication facilities broke ground in the United States in 2025. Each one represents a multi-billion-dollar investment in cleanroom infrastructure. And every cleanroom — regardless of whether it is manufacturing advanced logic chips, memory, or power semiconductors — requires a validated decontamination program that governs how its controlled environments are cleaned, decontaminated, and returned to production-ready state.

The contamination control problem inside a modern semiconductor fab is not as distant from pharmaceutical cleanrooms as it might appear. The physics are identical. The engineering solutions overlap substantially. And VHP — vaporized hydrogen peroxide — has become the preferred decontamination method for the applications inside fabs where contamination control matters most.

The Scale of What Is Being Built

The CHIPS Act implementation funded domestic manufacturing investments across the semiconductor supply chain — from advanced logic to memory to packaging to equipment. The facilities currently under construction or recently completed represent the largest domestic semiconductor buildout in U.S. history:

Micron Technology's fabrication campus in Clay, New York is one of the most cited CHIPS Act projects — a 2.4 million square foot complex that will ultimately house multiple cleanroom bays producing DRAM memory. Intel's Ohio campus in Licking County — two fabs initially, with capacity for eight — represents a $20 billion initial investment, the largest private investment in Ohio's history. TSMC's Arizona campus in Phoenix is producing 4-nanometer and 3-nanometer advanced logic chips. Samsung's Taylor, Texas facility adds to its existing Austin campus. Texas Instruments is building 300mm wafer fabs in Sherman, Texas and Lehi, Utah.

These are the headline facilities. Behind them are dozens of smaller investments: compound semiconductor fabs, silicon carbide manufacturing facilities, advanced packaging facilities, photomask shops, and specialty equipment manufacturers who are co-locating with major fab customers. Each of these requires cleanroom space. Each cleanroom requires a contamination control program.

Why Semiconductor Fabs Need Decontamination Programs

The contamination sensitivities of a semiconductor fabrication environment are different in specifics but identical in structure to pharmaceutical cleanrooms.

In a pharmaceutical cleanroom, the contamination concern is biological: bacteria, fungi, spores, and endotoxins that can compromise product sterility or patient safety. The cleanroom is designed to exclude and remove biological contamination, and decontamination events — using VHP or sporicidal agents — are executed when contamination events occur, during maintenance windows, or as part of periodic decontamination schedules.

In a semiconductor cleanroom, the contamination concerns are physical and chemical: particles, molecular contamination, and airborne molecular contaminants (AMCs) that deposit on wafer surfaces and cause defects in patterned circuits. At advanced node geometries — 3 nanometers, 2 nanometers, and below — a single particle of the wrong size in the wrong location causes a defect that fails the circuit. The yield consequences of contamination in advanced node manufacturing are directly calculable: each defect per unit area translates to a predictable percentage of chips that fail functional testing. At these economics, contamination control is not a regulatory compliance activity. It is a yield management discipline with direct financial impact measured in hundreds of millions of dollars per year.

The decontamination events that require VHP in semiconductor fabs are specific and predictable: pass-through box decontamination, tool chamber decontamination following maintenance, mini-environment decontamination, and full-room decontamination during facility qualification or post-incident recovery. Each of these has its own contamination profile, its own decontamination cycle requirements, and its own validation framework.

Pass-Through Boxes: The Highest-Frequency Application

The highest-frequency VHP application in a semiconductor fab is pass-through box decontamination — a function that operates continuously throughout production.

Pass-through boxes (also called load locks or equipment front-end modules, or EFEMs) are the transfer chambers through which materials enter and exit the controlled cleanroom environment. Wafers move through pass-through boxes when entering a processing tool; cassettes move through them when being transferred between production areas; maintenance equipment enters through them when tool access is required. Each transfer event represents a potential contamination pathway — materials from outside the cleanroom environment are entering it.

VHP decontamination of pass-through boxes is now the industry standard approach for managing this contamination pathway. The VHP cycle — injection of hydrogen peroxide vapor at calibrated concentration, dwell at the contact time required to achieve the target log-reduction for the organism of concern, then aeration to safe residual levels — can be executed in the transfer time window between material introduction and process initiation. The cycle is short (typically 15–45 minutes depending on chamber volume and target log-reduction), leaves no chemical residue after aeration (hydrogen peroxide decomposes to water and oxygen), and is compatible with the materials inside the pass-through box environment.

ISO 14644, the international standard series governing cleanrooms and associated controlled environments, provides the particle cleanliness classification framework within which semiconductor fabs operate. VHP decontamination is compatible with ISO 14644 environments: the vapor-phase delivery mechanism does not generate particles, the hydrogen peroxide residue profile after full aeration is acceptable in ISO Class 1–5 environments, and the temperature range (30–50°C) is within the thermal tolerance of semiconductor manufacturing equipment.

Tool Chamber Decontamination

When a semiconductor processing tool undergoes maintenance — a periodic requirement for any high-use production system — the tool chamber is opened to the cleanroom environment, work is performed by technicians, and the chamber must be decontaminated before it returns to production. This decontamination step is critical: a tool chamber that has been opened is no longer in its validated process-ready state. Particles introduced during maintenance, biological contamination from technician access, or surface contamination from maintenance materials must be eliminated before the tool resumes wafer processing.

VHP is the preferred method for tool chamber decontamination because it achieves the sporicidal efficacy required for a controlled environment return-to-production protocol without leaving residue that would contaminate the first wafer lot processed through a re-qualified tool. The four-phase VHP cycle — conditioning (establishing the temperature and humidity baseline), desorption (driving moisture off surfaces to enable VHP adsorption), sterilization/decontamination (VHP injection at calibrated concentration for the required dwell time), and aeration (catalytic decomposition of residual VHP to water and oxygen) — maps directly to the tool re-qualification workflow.

The parametric precision required for tool chamber decontamination is non-trivial. Tool chambers vary significantly in volume, surface material composition, and geometry. The VHP cycle parameters — concentration, temperature, humidity, dwell time — must be developed specifically for each tool type, with biological indicator placement at locations that represent the worst-case decontamination challenge within the chamber geometry. This is the same validation logic that governs VHP process development for medical device sterilization chambers: the cycle must be demonstrated to achieve the target log-reduction at the most challenging location, not at the easiest one.

Full-Room Decontamination: Facility Qualification and Incident Response

Full-room VHP decontamination in semiconductor fabs occurs in two contexts: new facility qualification and post-incident recovery.

When a new fab completes construction and cleanroom systems commissioning, the facility undergoes a qualification sequence that includes full-room decontamination. This establishes the contamination baseline for the production environment before any wafer processing begins. The decontamination event is part of the facility's validation record — evidence that the environment was brought to a defined contaminated state and successfully decontaminated to the target level before the first production lot was processed.

Post-incident decontamination occurs when a contamination event exceeds the facility's normal control thresholds — a spore-forming organism detected in environmental monitoring, a tool incident that causes localized contamination spread, or a maintenance event that results in visible contamination of a production area. In each case, production is halted, the affected area is isolated, VHP decontamination is executed per a validated decontamination protocol, the area is cleared through environmental monitoring, and production is resumed. The speed and reliability of this recovery sequence directly affects yield loss from the production interruption.

The Structural Parallel to Pharmaceutical Cleanrooms

The contamination control framework for semiconductor fabs is structurally identical to pharmaceutical cleanrooms, and this parallel is not coincidental — it reflects the same underlying physics.

In both environments, the contamination of concern deposits on surfaces and in air. In both environments, the decontamination method must achieve a defined level of contamination reduction (expressed as log-reduction in pharma, as particle count reduction in semiconductor). In both environments, the decontamination method must be compatible with the materials in the environment, must not leave residue that affects subsequent processes, and must be validated against a defined worst-case challenge.

VHP meets these requirements in both environments because its properties are a consequence of chemistry, not application context. Hydrogen peroxide vapor at sporicidal concentrations eliminates the biological contamination that pharmaceutical cleanrooms must control. The same vapor at the same concentrations eliminates the biological and organic contamination that semiconductor fabs must control as part of their comprehensive contamination program. The no-residue profile — hydrogen peroxide decomposes completely to water and oxygen — is equally important in both contexts: pharmaceutical products cannot tolerate hydrogen peroxide residue, and semiconductor wafer surfaces cannot tolerate chemical surface contamination from an incompletely aerated decontamination cycle.

PuroGen's position at this intersection is not a product line extension. It is a natural extension of the same contamination control science that VHP sterilization embodies — parametric precision, no-residue profile, and validated cycle development against defined worst-case challenges — applied to environments where the contamination consequences are financial rather than clinical, but where the physics, the engineering, and the validation logic are the same.

What "Validated Decontamination" Means in a Fab Context

The validation framework for semiconductor fab decontamination has historically been less formal than pharmaceutical sterilization validation. Pharmaceutical sterilization operates under FDA QMSR, ISO 13485, and ISO 22441 — a defined validation lifecycle with IQ/OQ/PQ requirements, biological indicator specifications, and submission-ready documentation. Semiconductor fab decontamination has operated under internal standards, equipment manufacturer specifications, and facility qualification protocols that vary by company and facility.

That gap is closing. As semiconductor manufacturing has moved to advanced nodes — where yield sensitivity to contamination is extreme and the cost of a contamination-related production interruption can reach seven figures per day — the industry has moved toward more rigorous decontamination validation frameworks. The same biological indicator-based performance qualification logic that pharmaceutical sterilization has used for decades is now appearing in advanced semiconductor fab decontamination protocols: defined biological challenge organisms (typically G. stearothermophilus spores for VHP), defined inoculation locations at worst-case geometry positions, defined performance targets (typically 6-log spore reduction), and documented PQ run data that supports the facility's contamination control program.

ISO 14644-5, which covers cleanroom operations, addresses decontamination as a controlled environment operational procedure and provides a framework for decontamination validation that parallels pharmaceutical approaches at a conceptual level. The specific biological indicator requirements, cycle development procedures, and documentation standards for semiconductor fab VHP decontamination are drawing increasingly on pharmaceutical validation precedent — a convergence that VHP system providers with deep pharmaceutical validation experience are positioned to support directly.

The CHIPS Act Buildout as a Market Signal

The 18 fabs that broke ground in 2025 represent a moment in the domestic semiconductor buildout that has direct implications for contamination control infrastructure. Each of these facilities will commission cleanroom decontamination programs during the facility qualification phase — before the first production lots are processed. The decontamination system selection, cycle development, and validation work that occurs during facility qualification establishes the contamination control architecture the facility will operate under for the next decade or more.

Facility qualification is not the time to evaluate an unfamiliar decontamination method for the first time. It is the time to deploy a validated approach, executed by providers with documented experience, producing a qualification record that supports the facility's long-term contamination control program. The concentration of new facility qualifications occurring simultaneously across the U.S. semiconductor sector in 2025 and 2026 is an infrastructure deployment moment of unusual scale — and contamination control programs are being designed and installed right now.

The CHIPS Act program office at the Department of Commerce has set domestic semiconductor manufacturing resilience as a strategic national objective. The infrastructure supporting that objective — cleanroom decontamination programs among it — is being built in real time. For contamination control providers with validated VHP expertise across both pharmaceutical and industrial cleanroom environments, the CHIPS Act buildout is not a future opportunity. It is an active deployment window.

Frequently Asked Questions

**Why is VHP preferred over other decontamination methods in semiconductor fabs?**

The no-residue profile is the primary driver. Semiconductor wafer surfaces have extreme sensitivity to chemical surface contamination — residues from cleaning or decontamination agents that are acceptable in other environments can cause defects at advanced node geometries. VHP decomposes completely to water and oxygen, leaving no chemical residue on surfaces after full aeration. This is the same property that makes VHP attractive for sterilizing drug-device combination products and temperature-sensitive biologics in pharmaceutical manufacturing. The chemistry is the same; the consequence of residue is different (wafer defects vs. product safety issues), but the requirement for residue-free decontamination is equivalent.

**What VHP cycle parameters are used for semiconductor fab decontamination?**

VHP cycles for semiconductor fab applications typically operate in the 30–50°C temperature range, which is within the thermal tolerance of cleanroom materials and installed equipment. VHP concentration ranges from approximately 250–1000 ppm depending on the application, chamber volume, and target log-reduction. The four-phase cycle — conditioning, desorption, decontamination, aeration — is the same structure used for pharmaceutical sterilization, with parameters developed specifically for each application through a cycle development and optimization process that validates performance at worst-case conditions. ISO 14644 compatibility is maintained throughout: the cycle does not generate particles, and the post-aeration residue profile is acceptable in ISO Class 1–5 environments.

**How does VHP compare to UV-C decontamination for semiconductor applications?**

UV-C achieves surface decontamination through photon-driven DNA damage in microorganisms on directly illuminated surfaces. Its primary limitation in complex geometries is line-of-sight dependence: surfaces that are shadowed from the UV source receive no decontamination benefit. VHP achieves decontamination through vapor-phase contact with all surfaces the vapor reaches, including geometrically complex or shadowed surfaces — provided the cycle parameters are developed to account for the geometry. For pass-through boxes, tool chambers, and cleanroom spaces with complex equipment geometry, VHP's non-line-of-sight mechanism is a direct advantage. UV-C remains useful for surface decontamination of simple, directly accessible areas, but VHP is the standard approach for enclosed-volume decontamination.

**What biological indicator is used to validate VHP decontamination in semiconductor fabs?**

Geobacillus stearothermophilus spores are the standard biological indicator organism for VHP decontamination validation, in both pharmaceutical and semiconductor applications. G. stearothermophilus is among the most VHP-resistant sporulating organisms, making it the appropriate worst-case challenge organism for cycle development and performance qualification. The same BI products used for pharmaceutical VHP validation — calibrated D-value strips or self-contained BIs — are applicable in semiconductor fab decontamination protocols.

**Does the CHIPS Act directly fund contamination control infrastructure?**

CHIPS Act funding supports facility construction, equipment procurement, and manufacturing capability development for semiconductor manufacturing facilities. Contamination control infrastructure — cleanroom systems, decontamination equipment, environmental monitoring — is part of the facility capital investment funded through CHIPS Act grants and associated private investment. The CHIPS Act program office has not designated contamination control as a separately tracked funding category, but it is embedded in the facility capital cost of every fab project receiving CHIPS Act support. The contamination control program is a prerequisite for facility qualification, which is a prerequisite for production, which is the purpose of the CHIPS Act investment.

**How does pharmaceutical VHP validation experience transfer to semiconductor fab decontamination?**

The validation logic transfers directly: define the contamination challenge, identify worst-case locations, inoculate with a calibrated biological indicator organism, develop cycle parameters that achieve the target log-reduction at worst-case locations, execute performance qualification runs, and document the results in a qualification record that supports the facility's contamination control program. The specific regulatory framework differs — pharmaceutical sterilization validation is governed by ISO 22441 and FDA QMSR, while semiconductor fab decontamination is governed by internal standards and ISO 14644-5 — but the technical methodology is the same. Providers with deep pharmaceutical VHP validation experience bring the most rigorous cycle development and qualification framework available to semiconductor fab decontamination programs.